TRENTON, N.J.--(BUSINESS WIRE)--With former hedge fund manager and best-selling author Jim Cramer calling biotech a safe harbor even with the uncertainty coming from Washington, C-Suite and other senior executives from New Jersey’s biotechnology and pharmaceutical industries will put the life science sector under the C-level microscope at BioNJ’s Inaugural CEO Summit as the biotechnology trade association Takes It to the Top on October 4 at the Bridgewater Marriott.
BioNJ today announced program details for Keynote Speakers and Panel Members.
Celgene Corporation Chairman and CEO Robert J. Hugin will discuss The Value of Medical Innovation for Patients, Healthcare and the Economy. “In the 21st century, medical innovation will dramatically improve health outcomes, producing a world that can be free from cancer and other challenging diseases, helping people live longer and better lives while reducing overall healthcare costs and stimulating the growth of the global economy,” Hugin said. “A continuation of pro-innovation and pro-patient policies will ensure a sustainable virtuous cycle of medical innovation, which will stimulate investment in bold and transformational science advancing the course of human health and creating economic progress and prosperity worldwide.”
André Wyss, U.S. Country Head/President of Novartis Corporation and President of Novartis Pharmaceuticals Corporation, will present Innovation is Key to Addressing Patient Needs in a Dynamic Marketplace. “A diversified clinical pipeline is vital to leading innovation and bringing new medicines to treat unmet patient needs,” Wyss said. “However, organizations must be adaptable to the ever-changing healthcare environment and take bold actions in every aspect of business. New ways of approaching business and connecting with diverse stakeholders is key to improving patient outcomes and ensuring success today and tomorrow.”
In Building a Biotech from Scratch: Lessons Learned, John F. Crowley, Chairman and CEO of Amicus Therapeutics, Inc., will discuss experiences through three biotech start-ups, including paths to financings, teambuilding, drug development, strategic partnerships and exits. Crowley will focus on how to prepare for and manage through the inevitable highs and lows of this dynamic and challenging industry.
Targeted panels offering new twists and perspectives include:
- In the Trenches with Tranches
- Inside Outsourcing
- How Wide is the Crack in the IPO Window?
- Billion Dollar Babies
“Access to capital is not a new issue to biotech; it’s THE issue and has been since the beginning,” said panel moderator James Marino, Esq., a Partner at Dechert LLP. “And today, it’s not even a question of whether new ways to access capital are needed; they are a necessity. There are new ideas out there, but which ones are working and what’s the best new thinking just beyond the horizon?”
Sorting out the strategies that hold the most promise for spurring continued growth will be panelists Lorenzo Pellegrini, Ph.D., Partner, Care Capital, LLC; Stuart Peltz, Ph.D., CEO, PTC Therapeutics, Inc.; Chris Tyrrell, CEO, OfferBoards; and Michael Wells, Managing Director, Princeton Biopharma Capital Partners LLC.
“Outsourcing is no longer a trend, everyone is doing it, but are they doing it right?” said moderator John Fraher, President of Aptalis Pharma. “The financial and logistical upsides for companies outsourcing everything from clinical research, to manufacturing, to sales and everything in between can be significant, but before taking the leap, management also needs to take a serious look at the myriad questions – from how to manage and guarantee quality to what does a company really ‘own’ at the end of the day.”
Fraher will guide a discussion on how to maximize benefits and minimize risks with panelists John Barry, Global Head, Vendor Strategies Management for Development, Merck & Co., Inc.; Sally Macaluso, Vice President, Janssen R&D Procurement, Johnson & Johnson; Ralph Marcello, Principal, Deloitte; Raymond Hill, President, inVentiv Health, Inc.; and John Watson, Corporate Senior Vice President,President, Strategic Partnering, and Chief Commercial Officer, Covance Inc.
“News reports have asked whether the IPO window is opening just a crack or if recent offerings are just the sound of a window seal break that will soon close after letting out some pent-up demand,” said moderator Hector G. Calzada, Jr., managing director, Deloitte Corporate Finance LLC. “Whatever the trend, the IPO remains elusively out of reach for many organizations – from startup to late-stage operations – that are intent on attracting financing and managing stockholder expectations.”
First-hand IPO experiences will be shared by panelists Kenneth I. Moch, President and CEO, Chimerix, Inc.; Christian S. Schade, Executive Vice President and CFO, Omthera Pharmaceuticals, Inc.; and Panna Sharma, President and CEO, Cancer Genetics, Inc.
Billion Dollar Babies will examine the challenges and achievements at several billion dollar New Jersey success stories. Moderator Julie Kampf, CEO and President, JBK Associates International, will be joined by panelists Anthony Marucci, Founder, President and CEO, Celldex Therapeutics, Inc.; Francois Nader, M.D., President and CEO, NPS Pharmaceuticals, Inc.; and Glenn Sblendorio, President and CFO, The Medicines Company.
Sponsors to date include: Amicus Therapeutics, Inc., Aptalis Pharma, Celgene Corporation, CohnReznick LLP, Dechert LLP, Deloitte, EisnerAmper LLP, Elusys Therapeutics, Inc., Ernst & Young LLP, Fisher Scientific, inVentiv Health, JBK Associates International, J. Knipper &Co., Korn/Ferry International, KPMG, Marke Communications, MDB Communications LLC, Morgan Lewis, New Jersey Center of Excellence, NPS Pharmaceuticals Inc., Pulse Productions, Reed Smith, Sheppard Mullin, Soligenix, Inc., Wilmington Trust, Yankee Public Relations and 6 Degrees Communication.
Registration for the event is $550 for BioNJ Members and $650 for Future Members. To register, please visit http://www.bionj.org/ceosummit2013/home-3 or call (609) 890-3185.
With more than 300 member companies, BioNJ is singularly focused on the growth and prosperity of New Jersey’s biotechnology cluster. Founded in 1994 by New Jersey industry CEOs, BioNJ serves as the voice of biotechnology companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate in New Jersey. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.